Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gefapixant - Merck

Drug Profile

Gefapixant - Merck

Alternative Names: AF-219; MK-7264; R1646; RG-1646; RO 4926219

Latest Information Update: 19 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer Merck & Co; Roche
  • Class Analgesics; Antiasthmatics; Antitussives; Pyrimidines; Small molecules; Sulfonamides; Urologics
  • Mechanism of Action Purinergic P2X3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cough
  • Phase II Asthma; Interstitial cystitis; Musculoskeletal pain; Pelvic pain
  • Discontinued Overactive bladder; Pain

Most Recent Events

  • 01 Feb 2019 Merck terminates a phase II trial for Cough in United Kingdom as the data did not support study endpoints for acute cough, based on an interim efficacy analysis (PO) (NCT03569033)
  • 31 Oct 2018 Phase-III clinical trials in Cough (Treatment-resistant, In adults) in Japan (PO) (NCT03696108)
  • 04 Oct 2018 Merck Sharp & Dohme plans a phase III trial for Cough in October 2018 , (NCT03696108)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top